Regulatory reform
India's system is built to approve generics and biosimilars. It needs the capacity to evaluate truly new drugs, so innovators don't lose three to four years.
Thirty years ago, as big pharma walked away from antibiotics, one Indian company kept going. Wockhardt's Founder Chairman talks about building new antibiotics in India, saving patients nothing else could help, and the reforms India needs next.
Can we make our antibiotic accessible equally, irrespective of your buying power? You have a drug, you make it available to as many people as possible.
A live model of an infection. Grey bacteria die quickly on the antibiotic, amber ones are tougher, and red ones are fully resistant. Bacteria double about every six hours. Try a full course, then try stopping early a few times, and watch the mix change.
Dr. Khorakiwala's point: bacteria can double every six hours, so a delay in the right treatment multiplies the infection. Drag to see.
Drug-resistant infections already kill more than a million people a year. These are the figures behind the episode.
people have died as a direct result of drug-resistant infections worldwide since you opened this page.
Estimate based on 1.14 million deaths a year directly caused by AMR, about 2 every minute. Source: GRAM Project, The Lancet (2024), data for 2021.Quotes are lightly edited for readability. Tap a quote's timestamp to hear it in context.
"You have to get the right antibiotic, at the right time, to the right kind of patients."
"Ordinary people should never use antibiotics on their own."
"For every six hours, the population of bacteria doubles. Every day is very precious for life."
"We intend to invest in antibiotic research over the next 20 to 30 years."
"India can definitely become an innovative hub in the world."
Asked to sum up, Dr. Khorakiwala named three priorities for the country's fight against AMR.
India's system is built to approve generics and biosimilars. It needs the capacity to evaluate truly new drugs, so innovators don't lose three to four years.
Bring the patent framework in line with Western markets so global companies invest and run research in India.
Don't simply hold new antibiotics back. Give the right drug at the right time, because every day of delay lets infection grow.
Three quick questions drawn from the episode and its explainers.
Led Wockhardt into antibiotic research some 30 years ago, when most large companies were leaving the field.